Treatment and services

Treatment of Opioid Use Disorder (9/2018, NJOTF): Discusses key issues surrounding medication assisted treatment (MAT), the evidence that underlies treatment types for opioid use disorder, best practices, and legal implications.

Medication-Assisted Treatment (MAT) (4/2019, SAMHSA)

Treatment Approaches for Drug Addiction (1/2019, National Institute on Drug Abuse)

Medications to Treat Opioid Use Disorder: How is opioid use disorder treated in the criminal justice system? (6/2018, National Institute on Drug Abuse): Useful to start a discussion on the current state of treatment.

Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions (2018, The American Journal of Drug and Alcohol Abuse)

Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder (6/2017, Journal of Adolescent Health)

Medication-Assisted Treatment of Adolescents with Opioid Use Disorders (9/2016, Pediatrics, American Academy of Pediatrics Committee on Substance Use and Prevention)

Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition) (1/2018, National Institute on Drug Abuse)

MAT Overview (SAMHSA-HRSA Center for Integrated Health Solutions)

Behavioral Health Treatment Services Locator (SAMHSA)

The Case for Medication-Assisted Treatment: MAT can help people with opioid use disorders, but few have access (1/2017, The Pew Charitable Trusts)

Medication-Assisted Treatment Improves Outcomes for Patients With Opioid Use Disorder (11/2016, The Pew Charitable Trusts)

Naloxone in Correctional Facilities for the Prevention of Opioid Overdose Deaths (4/2015, National Commission on Correctional Health Care)

Medication Assisted Treatment Studies

Drug Trials Snapshot: LUCEMYRA (5/2018, U.S. Food and Drug Administration)

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. (2/2018, Nunes EV, et al.)

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. (1/2018, Lee JD, et al.)

Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. (4/2016, Hser YI, et al.)

Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. (5/2015, Weiss RD, et al.)

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. (1/2014, Hser YI, et al.)

Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. (12/2011, Weiss RD, et al.)

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. (4/2011, Krupitsky E, et al.)

Treatment of Substance Use Disorder (SUD)

The ASAM Criteria (American Society of Addiction Medicine)

Patient Resources (American Society of Addiction Medicine): Dynamic patient resource guide to addiction.

Finding Quality Treatment for Substance Use Disorders (4/2018, Substance Abuse and Mental Health Services Administration - SAMHSA)

Treatment Approaches for Drug Addiction (1/2018, National Institute on Drug Abuse)

Rx Pain Medications Know the Options, Get the Facts (11/2017, SAMHSA): Patient education fact sheet focusing on alternative pain management methods.

National Center for Trauma-Informed Care and Alternatives to Seclusion and Restraint (NCTIC) (9/2017, SAMHSA)

Treatment: Brief Description (6/2014, National Institute on Drug Abuse)

Program Profile: Interim Methadone Maintenance (IM) (6/2011, National Institute of Justice)

Program Profile: Methadone Maintenance Treatment (6/2011, National Institute of Justice)

Program Profile: Prize-Based Incentive Contingency Management for Substance Abusers (6/2011, National Institute of Justice)

Brief Interventions and Brief Therapies for Substance Abuse (1999, SAMHSA): Brief intervention and therapy techniques for the treatment of alcohol and drug misuse.

Medication Assisted Treatment of Opioid Use Disorder (OUD)

Naloxone Use in the Courthouse – A Judicial Bench Card (4/2019, NJOTF): Describes the signs of overdose, what to do if one occurs, how naloxone can be used to reverse the toxic effects of an overdose, and suggestions for a naloxone policy.

Overdose Reversal Toolkit (Addiction Policy Forum)

Medications to Treat Opioid Use Disorder (6/2018, National Institute on Drug Abuse)

Opioid Overdose Prevention Toolkit (6/2018, SAMHSA): Useful document, especially for taskforces.

Opioid Overdose Reversal with Naloxone (Narcan, Evzio) (4/2018, National Institute on Drug Abuse): Useful as a quick primer on naloxone for anyone who has not heard of it.

TIP 63: Medications for Opioid Use Disorder – Full Document (Including Executive Summary and Parts 1-5) (2/2018, SAMHSA)

Medication-Assisted Treatment for Opioid Use Disorders in Drug Courts (8/2016, National Drug Court Institute)

Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update (3/2016, SAMHSA)

Medication-Assisted Treatment of Opioid Use Disorder Pocket Guide (3/2016, SAMHSA)

The Facts about Buprenorphine for Treatment of Opioid Addiction (8/2015, SAMHSA)

The ASAM National Practice Guide for the Use of Medications in the Treatment of Addiction Involving Opioid Use (6/2015, American Society of Addiction Medicine)

Federal Guidelines for Opioid Treatment Programs (3/2015, SAMHSA)

Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide (12/2014, SAMHSA)

Medication-Assisted Treatment in Drug Courts: Recommended Strategies (2015, Legal Action Center)

Adult Drug Courts and Medication Assisted Treatment for Opioid Dependence (9/2014, SAMHSA)

Program Profile: Buprenorphine Maintenance Treatment (6/2011, National Institute of Justice)

Medication Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: A Treatment Improvement Protocol TIP 43 (2005, SAMHSA)